The F09C panel reviews fellowship applications dealing with basic, translational, and clinical science in cancer immunology and immunotherapy of cancer. It encompasses scientific disciplines covered by the Cancer Immunopathology and Immunotherapy (CII) scientific review group and a subset of disciplines covered by the Tumor Microenvironment (TME) scientific review group.
The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
- Tumor vaccines
- Antibody and antibody-based constructs, including antibody-drug conjugates (ADCs), to deliver cancer therapy or to activate anti-tumor immune responses
- Adoptive immunotherapy (tumor-infiltrating lymphocytes, chimeric antigen receptor and T cell receptor-engineered T cells, natural killer cells)
- Immunological aspects of cancer
- Interactions between tumor cells and immune cells.
- Predictive biomarkers of a patient or tumor’s clinical response to immunotherapies
- Tumor metabolic reprogramming in cancer immunology and immunotherapy
Shared Interests and Overlaps
Fellowship panels are broad and cover inter-related areas. Assignments are made based on the primary emphasis of the proposed research and topics in several fellowship panels overlap as described below. Final assignments are made by the staff at the Center for Scientific Review to ensure that each application has the appropriate expertise to review it.
There are shared interests with the Fellowship: Oncological Sciences Fellowship Panel (F09B) fellowship panel in mechanisms of cancer therapeutics and tumor microenvironment. Applications that focus on immunotherapeutic strategies and immune cells in the tumor microenvironment may be assigned to F09C. Applications that focus on non-immunological therapies and interactions between tumor cells and stromal cells may be assigned to F09B.
There are shared interests with the Cell Biology, Developmental Biology and Bioengineering (F05) fellowship panel in bioengineering. Applications that use biomaterials and engineered tissues to answer biological questions in tumor immunology or immunotherapy may be assigned to F09C. Applications that focus on development of new biomaterials, engineered tissues or drug delivery systems may be assigned to F05.
There are shared interests with the Immunology (F07) fellowship panel in tumor immunology. Applications that focus on translational aspects such as cancer prevention and diagnosis, development and evaluation of immunotherapeutic strategies and interactions between tumor cells and immune cells in the tumor microenvironment may be assigned to F09C. Applications that focus on mechanistic and immunological aspects such as the innate and adaptive immune responses to tumor cells may be assigned to F07.